Redeye terminates its coverage of Devyser Diagnostics and will cease providing research following qu...
Redeye comments on Alzinova’s announcement of a new research collaboration with Amsterdam UMC aimed ...
Redeye expects a broadly stable Q1 2026 report from Addnode, with acquisition-driven growth across D...
* Relatively light comps in Q1e, but market still tough * We raise '26e-'28e EBIT by 1-3% * Trading ...
CEO Mohan Frick and Chairman Robin Sukhia discuss the company’s proposed restructuring, the Nasdaq v...
We lower our forecasts slightly and retain our Base Case of SEK338 ahead of Lime’s Q1 2026 results.
Redeye comments on ExpreS2ion’s finalized rights issue of approximately SEK53m, including free-of-ch...
Duell is set to report Q2 (Dec-Feb) on Thursday, April 9.
Redeye returns with an update on FluoGuide, which is set to enter a catalyst-rich 2026 with multiple...
Redeye reinforces its positive view of CombinedX following a value-creating divestment, highlighting...
Yesterday, Scandinavian ChemoTech reported its best-ever Q1, with Animal Care sales of USD299k (~SEK...
* Q1'26 numbers due on 29 April at 07:45 CET * Near-term caution, but the model should continue to p...
The FX effect is partly erased by negative cuts to our organic sales growth assumptions.
Redeye comments on Isofol’s announcement of the outcome of its TO1 warrant exercise.
Redeye shares its view on Sleep Cycle ahead of the Q1 report, as the company’s evolution into a dive...
A directed issue of SEK2.55m, settled via debt offset by insiders, provides some balance sheet relie...
Redeye retains its positive view and Base Case in q.
* Strong A15 contribution, ’26e production up ~20% * Recent Brage updates imply ~NOK 0.
* Q1: Sales of EUR 44m (39m), EBIT of EUR 2.5m (0.8m) * 4% '26e EBIT raised following continued stre...
